DDInter1835 DDInter1676
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Topotecan {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Topotecan {u} (Compound) binds {v} (Gene) TOP1
Topotecan {u} (Compound) upregulates {v} (Gene) ALDH5A1
Topotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topotecan {u} (Compound) downregulates {v} (Gene) CCNF
Topotecan {u} (Compound) causes {v} (Side Effect) Mucosal inflammation
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Topotecan (Compound) treats peripheral nervous system neoplasm (Disease)
Topotecan (Compound) binds TOP1 (Gene)
Topotecan (Compound) upregulates ALDH5A1 (Gene)
Topotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Topotecan (Compound) downregulates CCNF (Gene)
Topotecan (Compound) causes Mucosal inflammation (Side Effect)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Topotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel